Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed
MSF Access Campaign answers three questions on the challenges accessing liposomal amphotericin B (L-AmB), a key drug for treating the deadly HIV opportunistic infection cryptococcal meningitis.
With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries
2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.
Dr Zulfiya Dustmatova works as a medical doctor with MSF in Tajikistan, where our teams work with the Ministry of Health and Social Protection to diagnose and treat children with drug-resistant TB (DR-TB).